Rashed Abdullah, Ph.D.

Rashed Abdullah, Ph.D. has a wealth of experience in the field of bioanalytics. Rashed began their career in 1998 as a Technician at the University of Vermont, where they were responsible for maintaining stocks of Murine Hybridomas, creating new monoclonal cell lines, and working with mice. In 1999, they moved to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, where they worked as a Research Scientist. Here they were responsible for training technicians, enhancing binding ADCC, affinity, and efficacy response of antibodies, and developing ELISA and other assays. In 2004, they joined Wyeth Vaccines as a Research Scientist, where they were involved in Aids Vaccine Research. In 2012, they began their PhD at St. Johns University, where their thesis focused on Elucidating the multimeric properties of Alpha-synuclein in Parkinson's disease. In 2018, they joined Abveris as a Senior Scientist-Antibody Discovery, where they were responsible for the development of monoclonal antibodies for use as therapeutics, reagents for clinical studies and general reagents use. In 2019, they were promoted to Senior Scientist- Bioanalytics Team Lead at Abveris. Most recently, in 2021, they joined Gennao Bio as a Principle Scientist.

Rashed Abdullah, Ph.D. obtained their Bachelor of Science in Biology from Montana State University-Bozeman between 1994 and 1996. Rashed then went on to obtain their Master's degree in Biology, General from St. John's University between 2012 and 2016. Finally, they completed their Doctor of Philosophy - PhD in Neuroscience from St. John's University between 2012 and 2017. Additionally, they obtained their Project Management Professional (PMP) certification from the Project Management Institute in May 2009.